Flexible Fill/Finish Solutions To Bridge The Clinical-To-Commercial Gap

David Pereira, Chief Operating Officer, and Jason Spacek, Chief Commercial Officer, Afton Scientific

The rapid evolution of the biopharmaceutical industry—driven by personalized medicine, complex drug modalities, and niche indications—is transforming the demands on sterile fill/finish manufacturing. Simultaneously, regulatory ambiguity, faster development timelines, and global volatility challenge how and where therapies are produced. Drug developers now need strategic, adaptable CDMO partners that can scale, shift formats, and manage technical complexity efficiently.

Afton Scientific exemplifies the next-generation CDMO, combining technical excellence, regulatory rigor, and operational flexibility. From sterile filling of vials, syringes, and cartridges to handling temperature-sensitive or highly potent drugs, Afton supports clients through all development phases. Their infrastructure, which includes ready-to-use (RTU) component filling lines, modular cleanroom space, and in-house labs, is designed for rapid tech transfer and scalable growth.

Flexibility is not just operational at Afton—it’s cultural. Clients have direct access to senior leadership, benefit from low staff turnover, and experience personalized service across every engagement. Even as Afton expands its capabilities, the company remains committed to its high-touch approach, ensuring service quality keeps pace with growth.

With a forward-looking infrastructure strategy and investments aligned with evolving market demands, Afton enables drug developers to respond to market shifts, manage regulatory complexity, and bring products to market faster. In a landscape where adaptability is the new competitive advantage, Afton Scientific stands out as a partner purpose-built for today’s sterile fill/finish challenges—and tomorrow’s innovations.